Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Hyun Kim (NPI 1457349771)

Field	Value
Entity Type	Individual
Organization	Hyun Kim
Address	2312 N Nevada Ave Ste 400
City	Colorado Springs
State	CO
ZIP	80907
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 11, 2005

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer Medicare: lifetime Medicare revenue is $1.3M and there is no Medicaid billing on file, so Medicaid does not appear in the payer mix for this NPI. That concentrated payer exposure means revenue trends will be driven primarily by Medicare policy and utilization shifts.

Revenue is highly concentrated in a small set of oncology drugs and imaging: the top three Medicare codes account for 71.5% of total Medicare revenue; J9271 generates $589.1K (47.1% of Medicare revenue), J9144 generates $218.9K (17.5%), and 78815 generates $86K (6.9%). This concentration indicates the practice derives most of its Medicare dollars from a few high‑value oncology services.

The code mix shows an infusion‑based oncology practice focused on immunotherapy and monoclonal antibody treatments: J9271 (pembrolizumab) and J9144 (daratumumab) are the two largest revenue drivers, and multiple chemotherapy administration codes (96413, 96401, 96365, 96367) are present. Presence of diagnostic radiopharmaceutical codes such as A9595 and PET/CT codes (78815, 78816) further supports a cancer‑diagnosis and treatment workflow that pairs systemic therapy with advanced imaging.

Competitive standing on the primary drug code is modest rather than dominant: J9271 ranks #786 of 1841 providers nationally (57th percentile), described in the file as "typical, unremarkable volume for this code," while J9144 ranks #445 of 615 (26th percentile) and is likewise labeled typical. These ranks suggest the provider is an active local participant in high‑cost immunotherapy administration but is not a top national center for these agents.

The provider uses specialized diagnostic imaging but at modest national standing: 78815 (PET/CT) ranks #2784 of 6566 providers (57th percentile) and A9595 (piflufolastat F‑18) ranks #375 of 528 providers (29th percentile), both noted as "typical, unremarkable volume for this code." This pattern indicates access to advanced imaging (including PSMA‑targeted PET) but not at volumes consistent with a regional imaging leader.

Clinic visit and ancillary service volumes are meaningful and relatively elevated: 99214 (325 claims, $29.3K) ranks #91343 of 479517 providers (81st percentile) and common lab/phlebotomy codes like 85025 (449 claims) and 36415 (468 claims) sit at the 84th and 88th percentiles respectively. Those higher percentiles, described in the file as typical for the codes, point to a steady outpatient visit schedule with onsite lab services supporting ongoing oncology care.

Tenure is long: the NPI was enumerated 2005-10-11 (~21 years ago), indicating an established practice likely supported by a sustained referral network and familiarity with Medicare processes. Long enumeration combined with the observed code mix suggests operational stability rather than a newly launched infusion center.

Operational sensitivity is high due to drug‑revenue dependence: with 71.5% of Medicare revenue coming from the top three codes, the provider’s financial performance is concentrated in a few high‑cost oncology drugs and related imaging. Given the ranks for those codes are generally described as "typical, unremarkable volume for this code," the practice appears to operate at customary national utilization levels but remains vulnerable to changes in utilization patterns or reimbursement for those specific codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,700	$40	$589.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,760	$40	$218.9K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	70	$1,210	$86K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	140	$530	$73.6K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,010	$30	$66.3K
J0897	Injection, denosumab, 1 mg	2,520	$20	$45.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	330	$90	$29.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$100	$26.3K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	10	$1,230	$15.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	110	$140	$15K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Hyun Kim — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	11	40	10,700	$40	$520.5K
J9144	20	20	7,560	$40	$354.8K
A9595	18	20	220	$540	$141.1K
J1568	20	30	2,240	$30	$101.5K
J0897	73	140	2,580	$20	$68.8K
78815	48	120	60	$540	$58.9K
J0881	11	10	7,670	$1	$23.4K
J3490	41	60	50	$290	$23.1K
96413	47	140	130	$100	$19.7K
78816	35	40	20	$480	$18.4K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Hyun Kim, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0
Sujatha Nallapareddy	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Hyun Kim, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
A Physicians Home Care	CO	In Home Supportive Care Agency	$0	$247.9M
A Circle Of Care Colorado, LLC.	CO	In Home Supportive Care Agency	$0	$101.8M
Goodwill Of Colorado	CO	Home Health Agency	$0	$33.3M
Stellar Care And Services, LLC	CO	Child Intellectual and/or Developmental Disabilities Respite Care	$0	$31M
Catholic Health Initiatives Colorado	CO	General Acute Care Hospital	$0	$25.2M
American Medical Response Of Colorado Inc	CO	Ambulance	$3.4M	$21.6M
Special Kids Special Families	CO	Developmentally Disabled Services Day Training Agency	$0	$24.8M
Lucas Inc	CO	Respite Care	$0	$23.6M
Achieve Whole Recovery, PC	CO	Specialist	$0	$22.7M
Loving Care Agency, Inc.	CO	In Home Supportive Care Agency	$0	$18.2M

Hyun Kim — Billing Profile & Reimbursement Data

Sign up for Hyun Kim — Billing Profile & Reimbursement Data policy alerts

Hyun Kim — Billing Profile & Reimbursement Data

Sign up for Hyun Kim — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References